AR027686A1 - USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD - Google Patents
USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOODInfo
- Publication number
- AR027686A1 AR027686A1 ARP010101290A ARP010101290A AR027686A1 AR 027686 A1 AR027686 A1 AR 027686A1 AR P010101290 A ARP010101290 A AR P010101290A AR P010101290 A ARP010101290 A AR P010101290A AR 027686 A1 AR027686 A1 AR 027686A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- coagulation
- extracorpore
- blood
- inhibiting substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere al uso de sustancias activas inhibidoras de la coagulacion, y especialmente de PEG-hirudina, para el tratamiento de individuos concirculacion extracorporea para la profilaxis de complicaciones vasculares después de la circulaci on extracorporea. Así se pueden tratar sobre todo losindividuos con insuficiencia renal cronica con requerimiento regular de hemodiálisis y de este modo pueden ser protegidos contra complicaciones vasculares, quecomunmente tienen una alta tasa de mor bilidad y mortalidad en los pacientes tratados en forma constante con diálisis.This refers to the use of active substances that inhibit coagulation, and especially PEG-hirudin, for the treatment of individuals with extracorporeal circulation for the prophylaxis of vascular complications after extracorporeal circulation. In this way, individuals with chronic renal insufficiency with regular hemodialysis requirements can be treated and can thus be protected against vascular complications, which usually have a high morbidity and mortality rate in patients treated constantly with dialysis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19010300P | 2000-03-20 | 2000-03-20 | |
EP00105867 | 2000-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027686A1 true AR027686A1 (en) | 2003-04-09 |
Family
ID=26070693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010101290A AR027686A1 (en) | 2000-03-20 | 2001-03-20 | USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1265639A1 (en) |
JP (2) | JP5367202B2 (en) |
AR (1) | AR027686A1 (en) |
AU (1) | AU2001248355A1 (en) |
CA (1) | CA2404115A1 (en) |
WO (1) | WO2001070273A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105102612B (en) | 2012-12-06 | 2020-11-17 | 恩立夫克治疗有限责任公司 | Therapeutic apoptotic cell preparations, methods of making and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158564B1 (en) * | 1984-03-27 | 1992-07-15 | Transgene S.A. | Expression vectors for hirudin, transformed cells and process for the preparation of hirudin |
JPH04503660A (en) * | 1988-12-05 | 1992-07-02 | バイオジェン インコーポレイテッド | Method and composition for inhibiting platelet aggregation |
CA2067224C (en) * | 1989-12-01 | 2001-02-13 | Manfred Kurfuerst | Hirudin/polyalkylene glycol conjugates |
JPH05168705A (en) * | 1991-06-11 | 1993-07-02 | Toray Ind Inc | System removing von willebrand factor |
JPH05220218A (en) * | 1992-02-13 | 1993-08-31 | Norio Nakabayashi | Anti-thrombogenic regeneration cellulose film and manufacture thereof |
DE4242655A1 (en) * | 1992-12-17 | 1994-06-23 | Behringwerke Ag | Use of thrombin inhibitors to inhibit ocular fibrin formation |
DE19715504C2 (en) * | 1997-04-14 | 2000-10-26 | Max Planck Gesellschaft | PMMA membranes with polyethylene glycol-coupled active substances |
JP3601662B2 (en) * | 1998-07-24 | 2004-12-15 | 東洋紡績株式会社 | Blood purification membrane with improved antithrombotic properties |
-
2001
- 2001-03-20 CA CA002404115A patent/CA2404115A1/en not_active Abandoned
- 2001-03-20 JP JP2001568469A patent/JP5367202B2/en not_active Expired - Lifetime
- 2001-03-20 AU AU2001248355A patent/AU2001248355A1/en not_active Abandoned
- 2001-03-20 EP EP01921346A patent/EP1265639A1/en not_active Ceased
- 2001-03-20 WO PCT/EP2001/003181 patent/WO2001070273A1/en active Application Filing
- 2001-03-20 AR ARP010101290A patent/AR027686A1/en unknown
-
2011
- 2011-08-26 JP JP2011184920A patent/JP2012006964A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003527442A (en) | 2003-09-16 |
AU2001248355A1 (en) | 2001-10-03 |
JP5367202B2 (en) | 2013-12-11 |
JP2012006964A (en) | 2012-01-12 |
CA2404115A1 (en) | 2001-09-27 |
WO2001070273A1 (en) | 2001-09-27 |
EP1265639A1 (en) | 2002-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Finkel et al. | THE CLINICAL APPLICATION OF CRRT—CURRENT STATUS: Complications of Continuous Renal Replacement Therapy | |
De Vries et al. | Fluid balance during haemodialysis and haemofiltration: the effect of dialysate sodium and a variable ultrafiltration rate | |
WO2001007067A3 (en) | Solutions and methods for inhibition of pain, inflammation and cartilage degradation | |
WO2009022417A1 (en) | Peritoneal dialysate | |
WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
PT1220670E (en) | USES OF L-CARNITINE AND ITS ALCANOYL DERIVATIVES AS OSMOTIC AGENTS IN SOLUTIONS FOR MEDICAL USE. | |
SE9900043D0 (en) | New use | |
Andreucci et al. | Edema and acute renal failure | |
ITMI20020526A1 (en) | VENOUS BLOOD TANK IN EXTRACORPOREAL CIRCUIT | |
AR027686A1 (en) | USE OF INHIBITING SUBSTANCES OF COAGULATION IN THE EXTRACORPORE TREATMENT OF BLOOD | |
EA200600695A1 (en) | PROTECTING TISSUE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS AND FORMATION | |
ES2198359T3 (en) | USE OF URODILATINE FOR THE TREATMENT OF CHRONIC RENAL FAILURE WITH RESIDUAL RENAL FUNCTIONS. | |
WO2002017952A3 (en) | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma | |
NZ514911A (en) | Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients | |
AR033089A1 (en) | ABSORBENT PRODUCT | |
Rogers | Indications for cadaver skin in burns and complex wound care: SA Burn Society Congress | |
WO2002015893A3 (en) | Treatment of wounds | |
SE0301546D0 (en) | Biocompatible polymer | |
FI952018A0 (en) | Use of BHAP in combination with other non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection | |
Krediet | Osmotic agents in automated peritoneal dialysis solutions | |
Scribner | Dialysis dose: higher is better. | |
DE602004028234D1 (en) | BIOKOMPATIBLE POLYMER | |
Wai-Leung et al. | Effects of peritoneal dialysate acidity on the net ultrafiltration and solute removal in patients on intermittent peritoneal dialysis | |
Palmer | Preventing Intradialytic Hypotension. | |
Shetty et al. | Ultrafiltration failure in CAPD |